Revolution Medicines (RVMD)
Health Care · biotechnology · NASDAQ
Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
What Revolution Medicines does
Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies for patients with RAS-addicted cancers. The company utilizes a proprietary research platform to discover and advance small-molecule drug candidates designed to inhibit specific signaling pathways that drive tumor growth.
Themes: precision oncology, targeted cancer therapy, oncology drug development
Fundamentals
- Price$188.12 as of 2026-10-08 close
- Market cap$40.3B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+293.4% 2025-10-08 close $47.82 → 2026-10-08 close $188.12
- P/En/a negative earnings
- ROE-69.3% FY2025, SEC XBRL
- Debt / equity0.40 as of 2026-09-02
- Beta1.05 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How RVMD compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RVMD is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: no growth data.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Revolution Medicines looks technically
Revolution Medicines (RVMD) is trading 27.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 251 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-08-03, breaking below its recent trading range. It is 16.1% below its highest point of the past year. Trading volume is running unusually high — about 2.4× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 27.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $203.48 | $203.48 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $147.10 | $147.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 211.51. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 251 trading days ago — a "golden cross", a bullish long-term signal | 251 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 17.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($180.51 to $211.51) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 24.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $224.31 | $224.31 |
|---|---|---|
| From the 52-week high | it is 16.1% below its 52-week high (its highest price of the past year) | -16.1% |
| Above the 52-week low | it is 312.5% above its 52-week low (its lowest price of the past year) | +312.5% |
| Below the 52-week high | it is 16.1% below its highest point of the past year | 16.1% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-03, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 30 trading days ago | 30 sessions |
| All-time high | its highest closing price on record is $224.31 (set on 2026-08-27) | $224.31 |
| Given back of the 52-week move | over the past year its closes ranged ($45.70 to $221.15), and it has given back roughly a quarter of its rise from last year’s low — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $107.11 to $112.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.8% |
| From the all-time high | it is 16.1% below its all-time high | -16.1% |
| Nearest price level | it is trading 3.2% below a resistance level at $194.19 — a price it turned at twice since 2026-07-09, most recently on 2026-07-27. Since 2024-10-08 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.2% |
| All-time low | its lowest closing price on record is $14.08 (set on 2022-05-12) | $14.08 |
| Above the all-time low | it is 1236.1% above its all-time low | +1,236% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.72 between its high and its low — about 4.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.72 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $188.00 and $211.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $188.00 – $199.96 – $211.93 |
| Typical daily range (% of price) | its price moves about 4.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.6% |
| Stretch from the 200-day average | it is trading 4.7 daily ranges above its 200-day average price (27.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.4× its 30-day average, a sign of heightened interest | 2.38× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.4% since the prior reading | +1.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.2% |
|---|
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.3 percentage points (the stock lost 9.3% while the market gained 1.0%) | -10.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.7 percentage points (the stock lost 0.9% while the market gained 3.8%) | -4.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 79.8 percentage points (the stock gained 97.3% while the market gained 17.5%) | +79.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 278.4 percentage points (the stock gained 293.4% while the market gained 15.0%) | +278.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 8.0% of the share price. | -1.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $145.81 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +29.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $203.61 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -7.6% |
Price levels it has turned at before
RVMD last closed at $188.12 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $194.19 | Resistance | 3.2% above the last close | turned there twice · 2026-07-09 to 2026-07-27 |
| $177.03 | Support | 5.9% below the last close | turned there twice · 2026-07-17 to 2026-07-29 |
| $150.72 | Support | 19.9% below the last close | turned there twice · 2026-04-28 to 2026-05-06 |
| $94.96 | Support | 49.5% below the last close | turned there twice · 2026-02-26 to 2026-03-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $211.51.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $153.05 and $175.38 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $211.51.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Unusually heavy trading volume · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 22 analysts
- Mean price target$257.47 range $179.00 – $320.00; median $257.50
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RVMD
- Consensus EPS estimate-$2.39 next reporting period, as of 2026-10-05
- Estimate change, 30 days+$0.05101 from -$2.44, on 2026-08-31, 35-day window
- Readings revised upward63% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the clinical-stage and has not yet received regulatory approval for any product candidates, leading to significant operating losses and no current commercial revenue.","Success is dependent on the progress and results of preclinical studies and clinical trials, which are subject to high rates of failure and uncertainty.","The company requires substantial additional capital to fund its research, development, and potential commercialization efforts."]
What changed in the latest 10-Q
AI-assisted comparison of RVMD's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) describes company as 'late-stage clinical oncology company' instead of 'clinical-stage precision oncology company'
- Newer filing adds: 'Daraxonrasib has been granted a non-transferable voucher for daraxonrasib in pancreatic ductal adenocarcinoma (PDAC) under the Commissioner's National Priority Voucher (CNPV) pilot program, Orphan Drug Designation (ODD) by the FDA and European Medicines Agency (EMA)'
- Newer filing adds description of new class of RAS(ON) Inhibitors: 'We have designed a new class of tri-complex RAS(ON) Inhibitors in order to overcome RAS-driven drug resistance and thereby extend the clinical benefit of RAS(ON) Inhibitors. We currently expect to initiate a first-in-human clinical trial from this class of RAS(ON) Inhibitors in the fourth quarter of 2026.'
- Newer filing adds RAS mutant epidemiology data with specific patient numbers: 'there are an estimated more than 190,000 new RAS mutant cancer diagnoses each year in the U.S. These include approximately 60,000 patients with NSCLC, representing approximately 30% of NSCLC diagnoses, approximately 75,000 patients with colorectal cancer (CRC), representing approximately 50% of CRC diagnoses, and approximately 56,000 patients with PDAC, representing more than 90% of PDAC diagnoses.'
- Newer filing mentions RASolute 305 study: 'comparing zoldonrasib in combination with the investigator's choice of either gemcitabine nab-paclitaxel or modified FOLFIRINOX against the investigator's choice of the chemotherapies in patients with 1L metastatic PDAC in a placebo-controlled study'
- Newer filing references RASolute 309: 'we expect to initiate RASolute 309, a global, randomized Phase 3 registrational trial evaluating the combination of da'
- Removed:
- Older filing (2025-11-05) contained explanation of tri-complex technology platform mechanism and RAS(ON) vs RAS(OFF) distinction that is not present in newer filing
- Older filing contained detailed discussion of different patient benefit scenarios for multi-selective vs mutant-selective inhibitors and combination strategies that is not present in newer filing
- Older filing contained description of 'first wave' of RAS(ON) Inhibitors and discussion of 'RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways' that is removed in newer filing
- Older filing mentions RASolve 301 study (daraxonrasib vs docetaxel in NSCLC) which is not mentioned in newer filing excerpt
- Older filing contained specific enrollment update for RASolute 302: 'We are winding down enrollment globally for RASolute 302 as we near completion of enrollment at all U.S. and international sites and currently expect a clinical readout in 2026' that is not in newer filing
- Older filing contained clinical data announcements and dates (September 10, 2025 and December 2, 2024 data cutoff dates) that are not present in newer filing
- Reworded:
- Newer filing removes reference to 'RAS companion inhibitors' from pipeline description; older filing stated pipeline 'comprises RAS(ON) inhibitors...and RAS companion inhibitors'; newer filing states pipeline 'comprises inhibitors that bind directly to RAS variants'
- Newer filing describes daraxonrasib as 'tri-complex inhibitor' instead of 'RAS-selective tri-complex inhibitor' (older filing)
- Newer filing adds 'European Medicines Agency (EMA)' designation alongside FDA for Orphan Drug Designation; older filing only mentioned FDA
- Newer filing expands Breakthrough Therapy Designation description to specify 'previously treated metastatic PDAC in patients with KRAS G12 mutations' as more explicit language than older filing
- Newer filing reorganizes product pipeline section with separate 'New Class of RAS(ON) Inhibitors' and 'Other Development Opportunities' subsections; older filing had different organizational structure
- Notes:
- Newer filing text appears to be truncated at end ('RASolute 309, a global, randomized Phase 3 registrational trial evaluating the combination of da'), limiting full comparison of later sections
- Older filing text also appears truncated at conclusion, limiting complete comparison of data announcement section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 79 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 41 sells ($33M) — 8 selling insiders
- Last 90 days · read to 2026-10-040 buys · 79 sells ($78M) — 9 selling insiders
- Last 180 days · read to 2026-10-040 buys · 112 sells ($103M) — 10 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-29. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RVMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding RVMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 33,218,075
- Reported value $6,221,081,069
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RVMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RVMD had 9,669,157 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RVMD had 4.51% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.24 days to cover at the same settlement.
- Reported short interest (shares) 9,669,157
- Short interest (% of shares outstanding) 4.51%
- Prior settlement (shares) 9,727,133
- Reported change -0.6%
- Days to cover (reported) 7.24
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Revolution Medicines is found in…
RVMD ranks in…
Frequently asked questions
What does Revolution Medicines (RVMD) do?
Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies for patients with RAS-addicted cancers. The company utilizes a proprietary research platform to discover and advance small-molecule drug candidates designed to inhibit specific signaling pathways that drive tumor growth.
What sector is Revolution Medicines (RVMD) in?
Revolution Medicines (RVMD) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is Revolution Medicines (RVMD) overbought or oversold right now?
Revolution Medicines (RVMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RVMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.